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Abstract: Tourette’s syndrome (TS) is a neurological disorder characterized by motor and vocal 
tics that typically begin in childhood and often are accompanied by psychiatric comorbidities. 
Symptoms of TS may be socially disabling and cause secondary medical complications. Pharma-
cological therapies remain the mainstay of symptom management. For the subset of patients in 
whom TS symptoms are medically recalcitrant and do not dissipate by adulthood, neurosurgery 
may offer an alternative treatment strategy. Greater understanding of the neuroanatomic and 
pathophysiologic basis of TS has facilitated the development of surgical procedures that aim 
to ameliorate TS symptoms by lesions or deep brain stimulation of cerebral structures. Herein, 
the rationale for the surgical management of TS is discussed and neurosurgical experiences 
since the 1960s are reviewed. The necessity for neurosurgical strategies to be performed with 
appropriate ethical considerations is highlighted.
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Introduction
Historical perspective
In 1825, Jean-Marc Gaspard Itard, the Chief Physician at the National Institute for 
Deaf Mutes in Paris, provided careful clinical observations of stereotypic movements 
and vocalizations in the 26-year-old Marquise de Dampierre:
[she] began to have convulsive contractions in her hand and arm muscles, which 
manifested themselves especially at the moments in which this [woman as a] child tried 
to write as she spread her hand over the characters that she traced. After this deviation, 
her hand movements returned to normal once more and were subject to her will until 
another jolt interrupted the operation of her hand once more...soon it became certain 
that these movements were involuntary and convulsive, as the muscles of the shoulders, 
the neck and the face participated in them. The malady continued to progress, spasms 
were propagated in the organs of the voice and of the speech, and this young woman 
uttered bizarre cries and words which made no sense (Itard 1825).
The socially disabling effects of the disorder were also clear to Itard:
Among the continuous and disordered movements which lead to these morbid 
contractions, those imparted by the organs of voice and speech are the only ones 
deserving all our attention as presenting the more rare phenomenon as well as constituting 
the most disagreeable inconvenience, one which prevents the person from attaining all 
the kindnesses society offers; because the disorder that she bears is proportional to the 
pleasure of which it deprives her...the more others seem revolted by her uncivilized 
statements, the more she is tormented by the fear of uttering them (Itard 1825).
Although George Beard (1880–1881) later described an additional ﬁ  fty patients with 
motor tics and echolalia, the disorder was eponymously named by Jean-Martin Charcot 
after his student Georges Gilles de la Tourette, who had written a two-part manuscript Neuropsychiatric Disease and Treatment 2008:4(6) 1112
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in 1885 describing nine affected patients, including the 
Marquise (Gilles de la Tourette 1885).
Clinical features of Tourette’s syndrome
The clinical features of Tourette’s syndrome (TS) as 
described by those original reports remain the basis for 
current diagnostic criteria. More specifically, both the 
Tourette Syndrome Classiﬁ  cation Study Group and the 
Diagnostic and Statistical Manual of Mental Disorders 
(DSM-IV) (The Tourette Syndrome Classiﬁ  cation Study 
Group 1993; Müller-Vahl 2002) currently require the 
presence of multiple motor and vocal tics (stereotyped, 
purposeless, and involuntary movements or sounds) daily or 
intermittently over the course of over one year, and with onset 
in childhood (prior to eighteen years of age for the DSM-IV). 
An additional essential diagnostic criterion is tic variability; 
that is, their severity, frequency, and affected anatomic 
location must vary over the course of the disorder (The 
Tourette Syndrome Classiﬁ  cation Study Group 1993).
Categorization of TS into subtypes according to the 
patient’s symptoms has been proposed (Shapiro et al 
1988; Robertson et al 1990; Jankovic 2001). Simple TS 
is characterized by the predominance of motor and vocal 
tics, whereas more complex subtypes feature coprolalia, 
copropraxia, echolalia, echopraxia, palilalia, and/or palipraxia 
(Robertson et al 1990; Jankovic 2001). Patients with TS 
may also commonly exhibit other behavioral symptoms 
(Gilbert   2006), such as attention deficit-hyperactivity 
disorder (Robertson 2000), obsessive compulsive disorder 
(Frankel et al 1986; Como 1995), self-injurious behaviors 
(Robertson et al 1989; Kurlan et al 1990; Leckman et al 1993; 
Houeto et al 2005; Anandan et al 2004; Ackermans et al 
2007), and/or anxiety disorders (Robertson 2000).
Treatment of TS symptoms is pursued if the symptoms 
adversely affect quality of life or cause medical complications 
(Singer 2001). Patients who exhibit mild symptoms may 
require only psychobehavioral therapies and the support 
of family, teachers, and TS support groups (Kurlan 1997; 
Müller-Vahl 2002; Visser-Vanderwalle 2007). Some patients 
may be able to avoid the use of pharmacological therapies 
since TS is unique as a hyperkinetic movement disorder 
in that patients describe the ability to suppress their tics 
(Demirkiran and Jankovic 1995), at least in part. Moreover, 
although patients typically demonstrate a chronic disease 
course, symptom remission may occur spontaneously in up to 
40% of patients by late adolescence and an additional 30% of 
patients may experience later symptom improvement (Bruun 
and Budman 1992; Leckman et al 1998; Babel et al 2001). 
Pharmacological therapies may be beneﬁ  cial for patients 
whose tics do not respond sufficiently to conservative 
treatments or are functionally incapacitating (Gilbert 2006). 
The association of tics with medical or psychiatric condi-
tions may necessitate more aggressive tic management. 
For example, TS has been associated with self-injurious 
behaviors requiring urgent medical attention (Robertson 
et al 1989; Kurlan et al 1990; Leckman et al 1993; Houeto 
et al 2005; Anandan et al 2004; Ackermans et al 2007), 
such as corneal and orbital injuries (Robertson et al 1990) 
and stab wound- inﬂ  icted injuries (Anandan et al 2004), 
or tic-induced medical complications, such as cervical 
myelopathy (Krauss and Jankovic 1996), limb fractures, 
and retinal detachments (Flaherty et al 2005). The variety of 
medications used to manage TS has included dopaminergic 
antagonists, benzodiazepines, calcium channel antagonists, 
and atypical neuroleptics (Kurlan 1997; Robertson and Stern 
2000; Jiménez-Jiménez and García-Ruiz 2001; Müller-Vahl 
2002). Botulinum toxin injections have been used to treat 
painful dystonic tics (Jankovic 1994). Medical therapies may 
be particularly useful even during the waning phase of tics 
in early adolescence since tics have been reported to worsen 
at that time before they may ultimately resolve (Leckman 
et al 1998). However, medical therapies may cause detri-
mental and intolerable side effects (Leckman 2002; Flaherty 
et al 2005) and, for a subset of patients with TS, are ineffec-
tive (Müller-Vahl 2002; Visser-Vandewalle 2007). As Kopell 
and colleagues (2003) note, the development of additional 
treatment strategies for this subset of patients is particu-
larly important given that the endpoint for unsatisfactorily 
managed neuropsychiatric disease is “dismal”.
Pathophysiology 
of Tourette’s syndrome
Anatomical studies
The development of surgical strategies for medically recalcitrant 
TS was enabled by efforts to localize an anatomical source of the 
symptoms. Psychodynamic theories prior to the 1970s sought 
to explain tics as resulting from suppressed aggression and 
“impaired functioning of the ‘motility controlling function of 
the ego’ ” (Mahler and Luke 1946; Flinn et al 1983). Autopsy 
ﬁ  ndings from patients with TS that demonstrated no speciﬁ  c 
anatomical pathologies or only subtle changes in the striatum 
seemed to support conceptions that tics had a psychogenic origin 
(DeWulf and van Bogaert 1941; Balthasar 1957). The search 
for an anatomical basis for TS using autopsy material is thought 
to be problematic, however, both because few post-mortem 
brains have been studied and most of those available have Neuropsychiatric Disease and Treatment 2008:4(6) 1113
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come from patients with long-standing disease and treatment 
that might confound the histological analyses (Mink et al 
2001; Frey et al 2006). Nevertheless, more recent studies 
have found abnormalities particularly in the basal ganglia and 
frontal cortex. For example, studies have reported decreased 
levels of dynorphin-like immunoreactivity in the striatum and 
globus pallidus (Haber et al 1986; Haber and Wolfer 1992), 
decreased subcortical levels of serotonin (Anderson et al 1992), 
increased numbers of neurons expressing parvalbumin in the 
globus pallidus pars internus (GPi) and decreased numbers of 
neurons expressing parvalbumin in the caudate nucleus and 
globus pallidus pars externus (GPe) (Kalanithi et al 2005). 
Interestingly, Itard had speculated that the symptoms of TS 
had a cerebral origin in his 1825 case report:
What is the nature of these strange convulsions, or to pose 
the question in a clearer manner, the seat of the irritation 
which provokes them? Considering that the muscles which 
move against the will belong to different motor apparatuses 
which are not managed by the same nerves, this irritation 
is not caused by any of them but at their common centre 
which is the brain.
Neuroimaging studies
Modern imaging studies lend further evidence for a 
neuroanatomic basis of TS. Asymmetric striatal volumes 
have been observed in magnetic resonance images 
(MRI) of patients with TS, with smaller striatal volumes 
suggesting abnormalities in striatal development or the 
loss of GABAergic interneurons that are thought to play 
a role in gating sensory information (Peterson et al 1993; 
Singer et al 1993). Abnormally smaller caudate volumes 
are thought to be predictive of the development of more 
severe tics in early adulthood (Bloch et al 2005) and have 
been associated with more severe symptoms in twin studies 
(Hyde et al 1995). Abnormalities of volume also have been 
observed in the lenticular nuclei (Peterson et al 1993; Singer 
et al 1993). These ﬁ  ndings are inconsistent, however, since 
other studies have found no signiﬁ  cant differences in basal 
ganglia nuclei volumes compared to those of normal control 
patients (Moriarty et al 1997; Zimmerman et al 2000), or 
have found increased caudate volumes in children with TS 
(Denkla et al 1991). Functional MRI has revealed activity 
in the neocortex, striatum, thalamus, parietal operculum, 
supplementary motor area, insular cortex, and cerebellum in 
association with tic generation (Peterson 2001; Bohlhalter 
et al 2006; Lerner et al 2007), while increased activity in 
the caudate and frontal and temporal cortices and decreased 
activity in the ventral GP, putamen and thalamus have 
been observed during tic suppression (Peterson 2001). 
Increased activation of the substantia nigra, ventral tegmental 
area, and basal ganglia structures of the direct pathway has 
also been associated with increased tic severity in nonmedi-
cated children with TS (Baym et al 2008). Positron emission 
tomography (PET) studies using 18F-ﬂ  uorodeoxyglucose in 
patients with TS demonstrate increased metabolic activity in 
the premotor and supplementary cortices and midbrain and 
concomitant decreased activity in the caudate and thalamus 
(Stoetter et al 1992; Eidelberg et al 1997) while in those 
studies using 15O-water found increased activity in cerebral 
regions associated with sensorimotor, language, executive 
and paralimbic functions, which was temporally related 
to both the expression of motor and phonic tics and their 
premonitory urges (Stern et al 2000). Finally, consistent with 
PET ﬁ  ndings of decreased glucose utilization, single photon 
emission tomography (SPECT) has revealed decreased 
regional blood perfusion of the basal ganglia, thalamus, and 
frontal and temporal cortices in TS (Peterson et al 1993).
Anatomic localization of TS symptom generation to 
the basal ganglia is consistent with current understanding 
of basal ganglia physiology. In a general sense, disordered 
cortico-striato-pallido-thalamo-cortical circuitry is thought 
to be etiologically-related to TS, although the speciﬁ  c nuclei 
and circuits responsible for the various symptoms remain a 
matter of continued investigation (Müller-Vahl 2002; Mink 
et al 2006). It has been suggested, for example, that simple 
motor tics could be due to abnormal activation of the motor 
cortex via thalamocortical pathways while involvement of 
premotor, supplementary motor, and cingulate cortices may 
be related to more complex motor tics (Stern et al 2000; 
Mink et al 2001). Inappropriate activity in Broca’s area, 
the frontal operculum, and the caudate nucleus could elicit 
vocal tics (Stern et al 2000; Mink et al 2001). Abnormal 
activation of the orbitofrontal region, which has been 
observed in obsessive compulsive disorder, may underlie 
the compulsions and urges that patients with TS experience 
(Stern et al 2000; Mink et al 2001). Alternatively, tics in TS 
may be due to abnormal activity within subsets of neurons 
within the caudate and putamen (Graybiel et al 1994; Mink 
et al 2001); indeed, microstimulation of discrete areas of the 
putamen in monkeys induces stereotypic movements akin to 
tics (Alexander et al 1985).
Neurotransmitter studies
Given the diversity of nuclei and circuits that may be involved 
in TS pathogenesis, the variety of neurotransmitter systems 
that are also implicated is not surprising (Jankovic 2001). 
In the frontal subcortical circuits alone, abnormalities in Neuropsychiatric Disease and Treatment 2008:4(6) 1114
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glutamate, dopamine, serotonin, GABA, acetylcholine, 
noradrenaline, opioid, and cannabinoid receptors are thought 
to be involved (Lavenstein et al 2003). The serotonergic 
system has been studied in particular: patients with TS 
have been found to have decreased levels of serotonin and 
its metabolite 5-hydroxyindoleacetic acid in their serum 
(Comings 1990) and cerebrospinal ﬂ  uid (Butler et al 1979), 
respectively, and post-mortem studies have found decreased 
serotonin levels in the brain stem (Swerdlow and Young 
2001). This latter ﬁ  nding is particularly relevant since seroto-
nergic projections from the medial raphe nucleus are known 
to project to regions implicated in tic generation, such as the 
prefrontal cortex, substantia nigra pars compacta, ventral 
tegmental area, striatum, and nucleus accumbens (Alex et al 
2005; Pehek et al 2006). These target structures are com-
ponents of the dopaminergic system and, thus, it has been 
hypothesized that it is not serotonergic dysfunction, per se, 
that induces tics, but rather its effects on the dopaminergic 
system (Harris et al 2006). Serotonin inﬂ  uences dopaminergic 
release via a number of receptors, including serotonin het-
eroreceptors and inhibitory and stimulatory somatodendritic 
receptors, and is involved in dopamine reuptake (Sershen et al 
2000; Alex et al 2005; Pehek et al 2006; Carta et al 2007).
Indeed, the most widely purported hypothesis to explain 
the etiology of TS concerns dopaminergic circuitry dysfunc-
tion. The ability of dopaminergic antagonists to suppress 
tics suggests that the dopaminergic system is hyperactive in 
TS (Jankovic 2001). The direct dopaminergic basal ganglia 
pathway is thus facilitated, and the indirect pathway inhibited, 
which results in thalamocortical over-activity (Visser-
Vandewalle 2007; Figure 1). Dopaminergic hyperactivity 
could arise due to alterations in dopamine release (Snyder et al 
1970; Singer et al 1982; Harris et al 2006). Imaging studies 
In TS suggest an “overactive DAT [dopamine transporter] 
system” (Harris et al 2006): for example, SPECT has 
demonstrated increased dopamine transporter binding in the 
striatum in patients with TS (Cheon et al 2004; Serra-Mestres 
et al 2004), suggesting an elevated density of presynaptic 
dopamine terminals and postsynaptic D2 dopamine receptors, 
particularly in the ventral striatum (Wong et al 1989; Ernst 
et al 1999; Wolf et al 1996; Albin et al 2003). In further study 
of D2 receptors using 11C raclopride PET, amphetamine chal-
lenge caused a 21% increase in intrasynaptic dopamine levels 
that was not observed in control patients (Singer et al 2002). 
Although D2 receptor density has correlated with TS symptom 
intensity in monozygotic twins (Wolf et al 1996), this has not 
been consistently observed (Wong et al 1997). The net result of 
increased DAT density is decreased tonic extracellular levels of 
dopamine, increased dopamine levels in the axon terminal, and 
dopamine receptor supersensitivity (reviewed in Harris et al 
2006). Alternatively, TS may result not from abnormalities 
of dopaminergic transmission but from changes in the resting 
Normal Tourette’s syndrome
cerebral cortex cerebral cortex
thalamus Thalamus
DA via D1 DA via D2 DA via D1 DA via D2
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Figure 1 Schematic representation of basal ganglia circuitry (modiﬁ  ed from Visser-Vandewalle et al 1997), with excitatory (glutamatergic) projections   and inhibitory (GAB-
Aergic) projections  . Normally, dopamine, acting via D1 dopamine receptors, has an excitatory inﬂ  uence on striatal projections to the GPi and, acting via D2 dopamine 
receptors, an inhibitory inﬂ  uence on striatal projections to the GPe, maintaining a balance between the activities of the direct and indirect basal ganglia pathways.   According 
to the dopaminergic hypothesis of TS pathophysiology, dopaminergic hyperactivity causes increased activity in the direct pathway (indicated by the heavier weighted lines) and 
decreased activity in the indirect pathway, which serves to enhance thalamocortical activity. In TS, the thalamus, caudate-putamen, and GPe become pathologically hyperactive, 
and the GPi and STN become pathologically hypoactive.
Abbreviations: GPi, globus pallidus pars internus; GPe, globus pallidus pars externus; STN, subthalamic nucleus; DA, dopamine.Neuropsychiatric Disease and Treatment 2008:4(6) 1115
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membrane potentials of striatal neurons whose response to 
dopamine is consequently affected (Mink et al 2001).
Animal studies
Animal models have been developed to better understand the 
pathophysiologic basis of TS (Swerdlow and Sutherland 2005, 
2006). Normally, a prestimulus can prevent a startle response 
elicited by a stimulus, but this has been found to be deﬁ  cient 
in TS (Castellanos et al 1996; Freudenberg et al 2007). This 
is thought to be due to deﬁ  cient “gating” of sensorimotor 
information and has been modelled in rodents, pigs, and 
nonhuman primates (Swerdlow et al 2001; Swerdlow and 
Sutherland 2005; Freudenberg et al 2007; Hadamitzky et al 
2007). In order to model the hyperactive basal ganglia and 
limbic circuitry thought to underlie TS, transgenic mice have 
been developed that have tonically hyperactive cortical and 
limbic circuits (Campbell et al 2000; McGrath et al 2000; 
Nordstrom and Burton 2002; Swerdlow and Sutherland 2005, 
2007). These rodents display tics as well as compulsive behav-
iors (Campbell et al 2000; McGrath et al 2000; Nordstrom and 
Burton 2002; Swerdlow and Sutherland 2005, 2007). Micro-
injection of the GABAA antagonist bicuculline in the limbic 
area of the GPe has also been shown to induce complex tics 
and compulsions in African green monkeys and may therefore 
provide an additional primate model of TS (Grabli et al 2004). 
In addition to enhancing understanding of abnormal TS neural 
circuitries, animal models could be used to test surgical thera-
pies before they are introduced to the clinical setting.
Neurosurgical lesions
Frontal lobe disconnection
Surgical disruption of basal ganglia circuits began to 
be employed for the treatment of TS in 1955 (Stevens 
1964; Figure 2, Table 1). The earliest studies focused on 
Figure 2 Sagittal magnetic resonance image demonstrating the sites of lesions for TS.
Notes: 1, frontal leucotomy; 2, cingulotomy; 3, zona incerta lesion; 4, thalamotomy; 5, hypothalamotomy; and 6, dentatotomy.Neuropsychiatric Disease and Treatment 2008:4(6) 1116
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Table 1 Clinical studies of neurosurgical lesions for Tourette’s syndrome
Study effects Study 
design
n Comorbid 
diagnoses
Lesion Outcomes Adverse
Baker 1962 Case 
report
1 anxiety Bimedial frontal leucuotomy • Follow-up: 1 year • frontal lobe abscess
• tics and panic attacks 
“markedly reduced”
Stevens 1964 Case 
report
1 – Transorbital lobotomy • Follow-up: 9 years • obesity
• signiﬁ  cant decrease in 
frequency, duration, and 
amplitude of tics
Hassler and 
Dieckmann 1970
Case 
series
3 OCD Thalamotomy (bilaterally; 
targeted rostral intralaminar and 
medial nuclei)
• Follow-up: time not 
speciﬁ  ed
• mood alterations
• Evaluation: techniques 
not speciﬁ  ed
• 70%–100% 
improvement of 
coprolalia and tics
Nádvorník et al 1972 Case 
report
1 not indicated Dentatotomy (bilateral) • Follow-up: time not 
speciﬁ  ed
• none reported
• decrease in motor 
tics and resolution of 
vocal tics
de Divitiis et al 1977 Case 
series
3 OCD Thalamotomy (unilateral, except 
for 1 patient who also received a 
contralateral thalamotomy)
• Follow-up: 
at least 1 year 
(exact time not 
speciﬁ  ed)
• “prolonged mental 
confusion” (1 patient)
• complete remission 
of tics for 1 year but 
then recurrence of 
symptoms 2 patients)
• no improvement of 
tics (1 patient)
Kurlan et al 1988 Case 
series
2 OCD Cingulotomy • Follow-up: time not 
speciﬁ  ed
• none reported
• transient 
improvement of tics
• slight improvement of 
ritualistic behavior
Kurlan et al 1990 Case 
series
2 OCD Cingulotomy (bilateral anterior; 
1 patient had procedure 
repeated 8 months after ﬁ  rst)
• Follow-up: up to 
2 years
• aseptic meningitis 
for patient who 
underwent two 
procedures
• Evaluation: clinical 
rating scales not 
utilized
• No effects on tics 
or coprolalia
Robertson et al 1990 Case 
report
1 SIB Cingulotomy (bilateral) • Follow-up: 2 years • mild apathy
intellectual 
impairment
• Evaluation: LOI, BDI • general intellectual 
impairment
difﬁ  culties with orga-
nization concentration
• 75% ↓ severity of tics
(Continued)Neuropsychiatric Disease and Treatment 2008:4(6) 1117
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Table 1 (Continued)
Study effects Study 
design
n Comorbid 
diagnoses
Lesion Outcomes Adverse
Leckman et al 1993 Case 
report
1 OCD Cingulotomy (bilateral 
anterior) and infrathalamic lesion 
(bilateral)
• Follow-up: 16 months • sepsis
Left cingulated and infra-thalamic 
lesions repeated 1 month later
• Evaluation: YBOCS, 
YGTSS
• dysarthria, dysphagia, 
dysphonia
• improvement in tics 
(YGTSS score ↓ from 
22 to 15)
• severe handwriting 
problems, 
micrographia
Sawle et al 1993 Case 
report
1 OCD, SIB Hypothalamus (anterior) and 
cingulotomy (inferior)
• Follow-up: 21 months • none reported
• by 19 months 
no clinical signs of 
Tourette’s syndrome
Baer et al 1994 Case 
report
1 OCD Cingulotomy (second 
cingulotomy performed 
18 months after the ﬁ  rst)
• Follow-up: 18 months 
(ﬁ  rst cingulotomy); 
13 months (second 
cingulotomy)
• none reported
• Evaluation: YBOCS, 
BDI, CGI scale
• by 18 months fol-
lowing 1st surgery, 
depression and anxiety 
improved, but OCD 
and tics not improved
• by 13 months 
following 2nd surgery, 
OCD, depression, and 
anxiety improved, but 
tics worse
Kulisevsky et al 1995 Case 
report
1 OCD Leucotomy 
(bilateral prefrontal)
• Follow-up: 39 years • bulimia, weight gain, 
compulsive smoking 
appeared 4 years after 
surgery and deemed 
to be surgical
• Evaluation: YBOCS, 
LOI, HDRS TBSA, TSGS
surgical side effects
• Disappearance of 
coprolalia, copropraxia, 
and OCD 5 years after 
surgery that recurred 
38 years later
Korzenev et al 1997 Case 
series
4 OCD Details regarding the lesion 
targets, follow-up period, 
evaluation techniques and 
effects on tics not speciﬁ  ed
Babel et al 2001 Case 
series
16 ADHD 
(3 patients)
ZI, LM, VL • Follow-up: 7 years 
(range 3.5–17 years) 
(11 patients); 5 patients 
lost to follow-up
• Cerebellar signs, 
dystonia, and 
dysarthria 
(11 patients)
9 patients – bilateral 
lesions
• Evaluation: Tic severity 
rating scale
• transient 
postoperative 
morbidity (6 patients)
(Continued)Neuropsychiatric Disease and Treatment 2008:4(6) 1118
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Table 1 (Continued)
Study effects Study 
design
n Comorbid 
diagnoses
Lesion Outcomes Adverse
ZI targeted in 15 patients • signiﬁ  cant 
improvement of both 
vocal and motor tic 
scores (33%–75% and 
25%–80% in tic severity 
reduction, respectively)
• hemiparesis 
(3 patients)
ZI and VL/LM in 11 patients • disabling hemiballism 
(1 patient)
Anandan et al 2004 Case 
report
1 SIB, OCD, 
ADHD
Cingulotomy (targeted area 
above corpus callosum) and 
urinating then limbic leucotomy 
(7 months afterwards, targeted 
area under caudate nucleus 
proximal to previous lesion site)
• Follow-up 
(cingulotomy): 
6 months
• Cingulotomy: 
headaches, difﬁ  culty
• initial period of 
improvement of SIB but 
then recurrence of tics 
and SIB
• Leucotomy 
headaches, drowsiness
• Follow-up 
(leucotomy): 
not speciﬁ  ed
• ↓ frequency and 
severity of SIB
Sun et al 2005 Case 
series
12 OCD SIB 
(4 patients)
Capsulotomy [targeted the 
anterior 1/3 ( 7 patients) 
or posterior 1/3 (5 patients) 
of anterior internal capsule], 
bilaterally
• Follow-up: 3–18 
months (mean 13.4)
• no severe, perma-
nent side effects
• Reduction of tics imme-
diately post-operatively 
after anterior internal 
capsule lesion; beneﬁ  ts 
decreased by 1 months 
post-operatively in 
5 patients; only 2 patients 
demonstrated 80% ↓ in 
tics over sustained time 
period
• transient urinary 
incontinence, memory 
complaints, confusion
• 4 patients with lesion 
of posterior internal 
capsule demonstrated 
signiﬁ  cant and sustained 
reduction of tics; 
1 patient had 50% ↓ 
of tics
• delayed side effects: 
increased sexual 
behavior (3 patients), 
immature behavior 
(2 patients), akathisia 
(2 cases)
Abbreviations: ADHD, attention deﬁ  cit hyperactivity disorder; BDI, beck depression inventory; CGI, clinical global improvement scale; HDRS, hamilton depression rating 
scale; LM, lamella medialis thalamus; LOI, leyton obsessional inventory; OCD, obsessive-compulsive disorder; SIB, self-injurious behaviour; TBSA, tyrer brief scale for anxiety; 
TSGS, tourette’s syndrome global scale;   VL, ventrolateral nuclei of the thalamus; YBOCS, yale-brown obsessive compulsive scale; ZI, zona incerta.
surgical disconnection of the frontal lobe. Stevens (1964) 
reported the details of the prefrontal lobotomy that James 
Watts had performed nine years earlier in a 37-year-old 
man who had become incapacitated due to his motor 
and vocal tics. Two years post-operatively, the patient 
demonstrated improvement in his symptoms, which persisted 
for at least an additional six years. His beneﬁ  cial clinical course 
could not be attributed entirely to the surgery, however, since Neuropsychiatric Disease and Treatment 2008:4(6) 1119
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he also began to use neuroleptics. Baker (1962) reported the 
apparently successful management of tics and panic attacks 
in a 22-year-old man with bimedial frontal leucotomy, 
but Moldofsky and colleagues’ (1974) found that these 
beneﬁ  ts did not persist. The longest reported duration of 
symptom control attributed to prefrontal leucotomy was that 
experienced by a 29-year-old man with TS in whom there 
was complete resolution of motor and vocal tics beginning 
ﬁ  ve years post-operatively and for thirty-three years thereafter 
(Kulisevsky et al 1995). Measurement of regional cerebral 
blood ﬂ  ow using 99Tc-hexamethlypropylene amine oxide 
SPECT showed bilateral frontal hypoperfusion (Kulisevsky 
et al 1995).
Cingulotomy
Demonstration of the efﬁ  cacy of frontal lobotomy procedures 
for TS was not clear, and as a result procedures that targeted 
the cingulate cortex were investigated as an alternative. 
Anterior cingulotomy had been used since 1948 to treat a 
variety of psychiatric disorders to disconnect neural circuits 
involving the cortex, limbic system, and basal ganglia 
(Whitty et al 1952; Ballantine et al 1987). Targeting the 
cingulate cortex for the treatment of TS seemed appropriate 
given its recognized role in mediating emotional experi-
ences and language and coordinated movements (Robertson 
et al 1990). Cingulotomy decreased tics by 75% by 2 years 
post-operatively in one patient (Anandan et al 2004) and 
provided enduring improvement in another (Sawle et al 
1993). In an imaging study that found normalization of 
preoperative hypermetabolism in the caudate nucleus 
and thalamus, the beneﬁ  cial effects of cingulotomy were 
ascribed nonspeciﬁ  cally to the disruption of abnormal basal 
ganglia-thalamocortical circuitry (Sawle et al 1993). Other 
case reports have not conﬁ  rmed those beneﬁ  cial effects of 
cingulotomy and found that the procedure had little effects 
on reducing either tic severity or frequency or seemed more 
efﬁ  cacious for other comorbid symptoms, such as SIB and 
OCD (Kurlan et al 1988, 1990; Robertson et al 1990; Baer 
et al 1994). Beckers (1973) has recommended against the 
use of cingulotomy because of its side effects, which have 
included the development of apathy, intellectual impairment, 
and difﬁ  culties with concentration.
Thalamotomy
Attenuation of the corticostriatal hyperactivity that is 
thought to underlie TS symptomatology has also been 
attempted by thalamic lesions. Cooper’s performance of 
a right and then, one year later, left chemothalamectomy 
in a 16-year-old girl with TS signiﬁ  cantly improved her 
tic frequency (Cooper 1962) and he later described his 
experience with thalamic lesions in six other patients with 
TS (Cooper 1969). Details for only one representative case 
were provided, in which surgery had no effect on the tics. 
The results of Hassler and Dieckeman (1970) were more 
promising: up to 14 coagulations were made stereotactically 
in each hemisphere in the medial, intralaminar, and ventrolat-
eral thalamic nuclei and between 70% and 100% subjective 
improvement of tic symptomatology was observed. The 
same nuclei have been targeted in 4 other reported patients, 
but complete tic resolution was observed in only one patient, 
and in the others tic improvement was only transient at best 
(de Divitiis et al 1977; Cappabianca et al 1987). A case 
report in which bilateral cingulotomies and infrathalamic 
lesions were made highlights the potential devastating 
complications of thalamic lesions (Leckman et al 1993). 
A 40-year-old man who underwent these procedures dem-
onstrated improvement of obsessive compulsive symptoms 
but persistence of motor and vocal and the left lesions were 
therefore repeated (Leckman et al 1993). The infrathalamic 
lesion was extended inferiorly within the red nucleus and 
included as well the H ﬁ  elds of Forel, the basal intralaminar 
nucleus of the thalamus, the subthalamic nucleus, efferent 
ﬁ  bres from the VTA and SNr, and the dentatorubrothalamic 
efferent ﬁ  bres from the cerebellum (Leckman et al 1993). 
Post-operatively the patient developed a number of severe 
neurological deﬁ  cits including dysarthria, dysphagia, gait 
and hand-writing difﬁ  culties, mild hemiparesis, abnormal 
extraocular movements, axial rigidity, and bradykinesia 
(Leckman et al 1993).
Lesions of other structures
Stereotaxy has facilitated the targeting of other deep-seated 
cerebral structures for the treatment of TS. In combination 
with lesions of the lamella medialis and ventrolateral nuclei 
of the thalamus, the zona incerta has been lesioned with 
significant reduction of tic severity (Babel et al 2001). 
Transient and permanent deﬁ  cits were experienced by 66% 
and 27% of patients (Babel et al 2001), with bilateral lesions 
carrying a higher risk of neurological morbidity, including 
hemiballism, dystonia, dysarthria (Babel et al 2001), and 
quadriplegia (Asam and Karrass 1981). Other structures 
targeted include the anterior limb of the internal capsule 
(Sun et al 2005), within which striatal circuits and circuits 
that connect orbitofrontal cortical and medial thalamic nuclei 
pass. Lesions of the posterior third of the anterior internal 
capsule provided more durable improvement of symptoms, Neuropsychiatric Disease and Treatment 2008:4(6) 1120
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which was thought to be due the greater efﬁ  cacy of posterior 
lesions to disrupt neural pathways connecting the basal 
ganglia and frontal cortex (Sun et al 2005). In one case 
report, lesions of the dentate nucleus reportedly attenuated 
motor and vocal tics, but neither rationale for targeting this 
cerebellar structure nor a proposed mechanism of beneﬁ  cial 
action were discussed (Nádvorník et al 1972).
Deep brain stimulation
Although neurosurgical lesions for TS have ameliorated 
symptoms for some patients, for others, benefits have 
not been apparent and lesions have been associated with 
a number of permanent and disabling side effects. Deep 
brain stimulation (DBS) emerged as a promising alternative 
therapeutic strategy to stereotactic lesions after its efﬁ  cacy in 
the treatment of tremor was demonstrated in 1987 (Benabid 
et al 1987). The similar clinical effects of lesions and high 
frequency stimulation (HFS) suggest that DBS may inhibit 
the activity of target structures, by depolarization blockade, 
synaptic inhibition, and/or the release of inhibitory neu-
rotransmitters (Benazzouz and Hallet 2000; Dostrovsky et al 
2002; Filali et al 2004; Lozano and Mahat 2004; McIntyre 
et al 2004; Chang et al 2008; Liu et al 2008; Montgomery 
and Gale 2008). Other studies suggest, however, that DBS 
has an excitatory effect on neurons and axonal pathways in 
the vicinity of the electrode (McIntyre et al 2004; Chang 
et al 2008; Liu et al 2008; Montgomery and Gale 2008), or 
that DBS works by modulating the pattern of neuronal ﬁ  ring 
(Fukada et al 2001; Garcia et al 2005; Change et al 2008; Liu 
et al 2008; Montgomery and Gale 2008). Regardless of its 
mechanism of action, compared to lesion procedures DBS has 
the advantage of being both reversible (since the electrodes 
can be removed if HFS ineffectively treats symptoms) and 
adjustable (since the stimulation parameters can be varied 
to elicit the most optimal clinical response). Benabid (2007) 
has thus referred to DBS as a “ﬂ  exible scalpel.”
Thalamic stimulation
Based upon the reported success of thalamic lesions in 
the control of TS symptoms, Visser-Vandewalle and 
colleagues (1999) performed HFS of the thalamus in a 
42-year-old man with medically recalcitrant TS (Table 2). 
They found that HFS of the thalamic targets of Hassler and 
Dieckemann (1970) signiﬁ  cantly reduced the number of 
tics by 4 months post-operatively, with complete resolution 
of the tics after 1 year. Clinical beneﬁ  ts were ascribed to 
deactivation of frontal cortical areas (via stimulation of the 
nucleus ventro-oralis internus) and corticostriatal circuits 
that involve the ventral (limbic) and dorsal (sensorimotor) 
striatum (via stimulation of intralaminar and medial thalamic 
nuclei). In a subsequent study in which three patients were 
followed up to ﬁ  ve years post-operatively, thalamic DBS was 
associated with a 72%, 83%, and 90% decrease in tics with 
complete resolution of all major vocal and motor tics (Visser-
Vandewalle et al 2003). Side effects of HFS included a slight 
sedative effect in all three patients and changes in sexual 
behavior in two (Visser-Vandewalle et al 2003). Servello 
and colleagues (2008) conﬁ  rmed the therapeutic efﬁ  cacy of 
thalamic DBS, albeit using targets different than those used 
by Visser-Vandewalle and colleagues, in their case series of 
eighteen patients in whom the centromedian-parafascicular 
and ventral oral thalamic nuclei were targeted. All patients 
demonstrated improvement in all four components of the Yale 
Global Tic Severity Rating Scale (YGTSS). By six months 
post-operatively, 3 patients’ tics had improved to the extent 
that they no longer required any adjunctive medical therapy. 
None of the patients experienced any disabling permanent 
side effects, but twelve patients required HFS adjustments. 
The ability for the effects of DBS to be tested in a double-blind 
manner was utilized in a recent prospective crossover trial 
(Maciunas et al 2007). Patients in whom bilateral thalamic 
DBS electrodes were implanted were assessed over four 
weeks, with one week spent in each of the following DBS 
states: both stimulators off, unilateral stimulation on the left 
or right, or bilateral stimulation (Maciunas et al 2007). The 
study’s primary and secondary outcome measures were met 
in that all patients demonstrated signiﬁ  cant improvements in 
Rush Video-Based Rating Scale (RVBRS) scores as well as 
YGTSS and TS Symptom List scores (Maciunas et al 2007). 
Ackermans and colleagues’ (2007) case report highlights that 
signiﬁ  cant adverse effects can occur due to the thalamic DBS. 
Their 39-year-old patient developed a vertical gaze paralysis 
due to hemorrhage in the upper mesencephalon at the caudal 
tip of one of the electrodes.
Pallidal stimulation
Attenuation of thalamic activity, indirectly, has also 
been attempted by HFS of the GPi in order to inhibit its 
pathological over-activity that is thought to ultimately lead 
to disinhibition of the thalamus and, thus, tics (van der 
Linden et al 2002; Diederich et al 2005; Houeto et al 2005; 
Ackermans et al 2006; Gallagher et al 2006; Shahed et al 
2007). van der Linden and colleagues (2002) found that 
bilateral GPi DBS decreased tics by 95% in a 27-year-old 
man with long-standing TS, which was greater than the 
suppression of tics induced by medial thalamic DBS (80%), Neuropsychiatric Disease and Treatment 2008:4(6) 1121
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Table 2 Clinical studies of deep brain stimulation for Tourette’s syndrome
Study Study 
design
n Comorbid 
diagnoses
DBS target(s) Outcomes Adverse effects
Vandewalle et al 1999 Case report 1 – Thalamus 
(rostral 
intralaminar and 
medial nuclei) 
bilaterally
• Follow-up: 1 year • none reported
• Evaluation: videotape 
analysis of tics
• complete abolishment 
of tics
van der Linden et al 
2002
Case report 1 depression Thalamus 
(medial) and GPi 
bilaterally
• Follow-up: 6 months • none reported
• Evaluation: not speciﬁ  ed
• 80% ↓ tics by thalamic 
DBS
• 95% ↓ tics by pallidal DBS
Visser-Vandewalle 
et al 2003
Case series 3 – Thalamus (at level 
of the Voi, Cm, 
Spv) bilaterally
• Follow-up: 8 months 
– 5 years
• reduced energy 
at stimulus voltage 
required for optimal tic 
management
• Evaluation: videotape 
analysis of tics
• increased sexual drive 
(1 patient)
• Resolution of all major 
tics
• reduced sexual 
function (1 patient)
• 3 revisions of pulse 
and cables because of 
pain generator traction 
(2 patients)
Flaherty et al 2005 Case report 1 – AIC (ventral) 
bilaterally
• Follow-up: 18 months • mood alteration (high 
nucleus voltage stimula-
tion at depression 
accumbens produced 
at and apathy, stimula-
tion capsule in body 
of internal produced 
hypomania)
• Evaluation: YGTSS
• 25% ↓ YGTSS in overall 
impairment
• 17% ↓ total tic score
- • 20% ↓ global severity
• 45% ↓ tic severity and 
frequency and increased 
ability to suppress tics 
(according to patient)
Diederich et al 2005 Case report 1 mild OCD GPi bilaterally • Follow-up:14 months • transient fatigue 
(several months)
• Evaluation: YGTSS, BDI, 
STAI, SCL-90-R
• impaired rapidly 
alternating pronation 
and supination 
movements of left limbs
(Continued)Neuropsychiatric Disease and Treatment 2008:4(6) 1122
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Table 2 (Continued)
Study Study 
design
n Comorbid 
diagnoses
DBS target(s) Outcomes Adverse effects
• 73% ↓ tic frequency /minute
• ↓ intensity of vocal tics
Houeto et al 2005 Prospective 
double blind
1 Anxiety Depression 
SIB
Ce-Pf of thalamus, 
GPi, or both
• Follow-up: 2 years • weight loss
• Evaluation: YGTSS, RVB-
TRS, MADRS, BAS, BIS
• Thalamic DBS: 64% ↓ 
YGTSS scores, 77% ↓ 
RVBTS scores
• Pallidal DBS: 66% ↓ YGTSS 
scores, 54% ↓ RVBTS 
scores
• combined DBS: 60% ↓ 
YGTSS scores, 77% ↓ 
RVBTS scores
• elimination of SIB
Ackermans et al 2006 Case series 2 OCD Patient 1: 
Thalamus 
(at level of Voi, 
Cm, and Spv) 
bilaterally
• Follow-up: 1 year • feeling of ↓ energy 
at required stimulus 
voltage reduction for 
optimal tic
• Evaluation: Videotaping and 
counting tics
• ↓ sexual functions
Patient 2: Thalamus 
(at level of Voi, Cm, 
and Spv) and GPi 
(postero ventro-
lateral) bilaterally
• ↓ tics [from 20 to 
3/minute (patient 1) and 
28 to 2/minute (patient 2)]
• dystonic jerk when 
stimulator activated
• Complete resolution of all 
major tics and compulsions
Gallagher et al 2006 Case report 1 – GPi bilaterally • Follow-up: “months” (time 
not speciﬁ  ed)
• Infection of 
stimulator lead
• evaluation of tics not 
discussed
Ackermans et al 2007 Case report 1 SIB Thalamus 
(medial part at 
crosspoint of Cm, 
Voi, hemorrhage 
and Spv) 
bilaterally
• effects on tics not 
discussed
• vertical gaze palsy due 
to intracerebral
Kuhn et al 2007 Case report 1 OCD nucleus accumbens 
and anterior limb of 
the internal capsule
• Follow-up: 2.5 years • none reported
• Evaluation:YGTSS, MRVRS, 
GAF, YBOCS
• 41%, 50%, and 52% 
remission rates in YGTSS, 
MRVRS, and YBOCS, 
respectively
• considerable improvement 
in psycho-social functioning 
(GAF ↑from 7 to 41)
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Table 2 (Continued)
Study Study 
design
nC omorbid 
diagnoses
DBS target(s) Outcomes Adverse effects
Maciunas et al 2007 Prospective, 
randomized, 
double-blind, 
crossover
5 ADHD 
(3 patients) OCD 
(4 patients) 
depression 
(5 patients)
Thalamus 
(Cm, Voi, and Spv) 
bilaterally
• Follow-up: 3 months • none related to the 
procedures
• Evaluation: YGTSS, SF-36, 
VAS, BDI-2, HAM-D, HAM-A, 
YBOCS TSSL, MRVRS
• Signiﬁ  cant ↓ in MRVRS 
(primary outcome measure) 
in bilateral on state
, • Signiﬁ  cant improvement in 
tic counts and YGTSS and 
TSLS scores (secondary 
outcome measures)
• Quality of life indices 
improved (SF-36 and VAS 
scores)
Shahed et al 2007 Case report 1 OCD, ADHD, 
Depression, anxiety
GPi bilaterally • Follow-up: 6 months • none reported
• Evaluation: YGTSS, TSSR, 
MRVRS YBOCS, SF-36 v2, 
BRIEF
• 84% ↓ total YGTSS scores
• 88% ↓ TSSR scores
• 21% ↓ MRVRS scores
• 65% ↑ SF-36 v2 scores
Servello et al 2008 Case series 18 OCD (9 patients) 
SIB (9 patients) 
Depression 
(3 patients) ADHD 
(1 patient)
Thalamus (Ce-Pf 
and Voi) bilaterally
• Follow-up: 3-18 months • none reported
• Evaluation: YGTSS
• 65% ↓ in YGTSS scores
• 17 patients demonstrated 
signiﬁ  cant improvement of 
tic severity
• 3 patients required no 
further medical Therapy
Abbreviations: ADHD, attention deﬁ  cit hyperactivity disorder; AIC, anterior internal capsule; BAS, brief anxiety scale; BDI, beck depression inventory; BIS, baratt’s impulsivity 
scale; BRIEF, behaviour rating inventory of executive function; Ce-Pf, centromedian-parafascicular complex of the thalamus; Cm, centromedian nucleus; GAF, global assessment 
of functioning scale; GPi, globus pallidus pars internus; HAM-A, hamilton rating scale for anxiety; HAM-D, hamilton rating scale for depression; MADRS, montgomery-asberg 
depression rating scale; MRVRS, modiﬁ  ed rush video rating scale; OCD, obsessive-compulsive disorder; RVBTS, rush video-based tic rating scale; Spv, substantia periventricularis; 
SCL-90-R, symptom checklist-90-R; SF-36, short form 36; SIB, self-injurious behaviour; STAI, state-trait anxiety Inventory; TSSL, tourette syndrome symptom list; TSSR, tic symptom 
self-report; v2, version 2; VAS, visual analog scale;   Voi, nucleus ventro-oralis internus; YBOCS, yale-brown obsessive-compulsive scale; YGTSS, yale global tic severity scale.
an effect that lasted at least six months. The efﬁ  cacy of 
thalamic or pallidal DBS was found to be similar in another 
case report, although tic attenuation occurred more abruptly 
with pallidal stimulation (Ackermans et al 2006). Houeto 
and colleagues (2005) also directly compared the efﬁ  cacy 
of pallidal versus thalamic DBS in their prospective double 
blind study. In one patient in whom electrodes were placed 
in the anteromedial GPi and centromedian-parafascicular 
complex of the thalamus, either thalamic or pallidal 
stimulation signiﬁ  cantly reduced tic severity and SIB to a Neuropsychiatric Disease and Treatment 2008:4(6) 1124
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similar extent. Symptoms relating to mood and impulsivity 
were better controlled by thalamic DBS, however. Diederich 
and colleagues (2005) provide up to fourteen months of 
follow-up data regarding their patient with bilateral DBS 
of the posteroventrolateral GPi. Tic frequency and intensity 
improved, as did the patient’s concomitant anxious and 
depressive symptoms. These beneﬁ  cial effects have been 
observed in two other case reports (Gallagher et al 2006; 
Shahed et al 2007).
Other targets for stimulation therapy
Other less frequently targeted structures include the anterior 
limb of the internal capsule and the nucleus accumbens 
(Flaherty et al 2005; Kuhn et al 2007). Using a more lateral 
and anterior target than has been used for the surgical 
treatment of OCD, DBS of the anterior limb of the internal 
capsule has been shown to decrease tic severity and frequency, 
but not to the extent that has been observed with thalamic 
DBS (Flaherty et al 2005). Stimulation of the electrode’s 
middle contacts resulted in the greatest improvement of 
tic symptomatology (Flaherty et al 2005). Interestingly, 
variation in voltage parameters affected the patient’s mood: 
HFS in the middle or dorsal-most contacts, which lay in the 
body of internal capsule, produced euthymia and hypomania, 
respectively, whereas stimulation of the ventral-most 
contacts, which was located near the nucleus accumbens, 
caused depression (Flaherty et al 2005). Kuhn and colleagues 
(2007) did not report any alteration of mood in their case 
report of HFS of the anterior limb of the internal capsule 
and fundus subventricularis of the nucleus accumbens, and 
found that it decreased their 26-year-old patient’s YGTSS 
and RVBRS scores by 41% and 50%, respectively.
DBS caveats
Despite their therapeutic promise for TS and apparent 
advantages compared with neurosurgical lesion procedures, 
DBS strategies also can be associated with a number 
of deleterious side effects and complications. While 
certain adverse events are common to both lesion and 
DBS procedures, such as intracerebral hemorrhage1 and 
the development of surgery-related infection or seizures 
(Hardesty and Sackheim 2007), others are unique to DBS. 
For example, patients with TS in whom DBS systems have 
been implanted have experienced poor healing , infections, 
or hardware malfunctions due to compulsions to repeatedly 
touch their incisions or push on the subcutaneously-buried 
hardware (Servello et al 2008; Shahed et al 2007; Sillay 
et al 2008). Limousin-Downey and Tisch (2005) suggest 
that patients with comorbid OCD symptoms may become 
obsessed with their DBS systems in terms of thoughts of 
“mind control”. Moreover, DBS requires ongoing surgical 
maintenance to replace pulse generators (Bin-Mahfoodh 
et al 2003), which last between several months to ﬁ  ve years 
depending upon stimulation parameters, manage hardware-
related complications (Oh et al 2002; Temel et al 2004; 
Constantoyannis et al 2005; Hamani and Lozano 2006), 
which have been noted to occur in up to 26% of cases, or 
adjust the stimulation settings. As has been reported for 
patients who have received DBS for Parkinson’s disease, 
HFS for TS may induce or exacerbate pre-existing psychiatric 
symptoms (Appleby et al 2007).
Surgical considerations
With DBS emerging as a promising therapeutic strategy 
for the management of TS, guidelines have been proposed 
regarding its use (Mink et al 2006; Hardesty and Sackeim 
2007; Okun et al 2008). Since TS symptoms, especially motor 
symptoms, may dissipate in late adolescence (Leckman et al 
1998), it has been suggested that surgical candidates be at 
least twenty-ﬁ  ve years of age, although Mink and colleagues 
(2006) acknowledge that selection of that age is somewhat 
arbritary. Patient selection should occur in a standardized 
manner. Patients should have their diagnosis of TS conﬁ  rmed 
by two independent clinicians and demonstrate recalcitrance 
to nonsurgical therapies (Singer et al 2001; Minks et al 2006; 
Visser-Vandewalle 2007). Visser-Vandewalle (2007) suggests 
that this entails a lack of, or at best only partial, response to 
three different classes of medications (antidopaminergic, anti-
psychotic, and experimental agents) and behavioral therapies. 
Patients should have tics severe enough to signiﬁ  cantly impair 
quality of life and/or pose medical risk, and this is suggested to 
correspond to a YGTSS total tic severity score of 35/50 for 
at least one year (which corresponds to tics that are frequent 
and noticeable in most situations most of the time) (Mink 
et al 2006). Patients unsuitable for surgical management 
include those who have a disorder other than TS, other severe 
psychiatric co-morbidities, structural cerebral abnormalities, 
or who have medical contraindications to undergoing surgery 
(Mink et al 2006; Visser-Vandewalle 2007). It is mandatory 
1The reported incidence of symptomatic intracerebral hemorrhage 
associated with stereotactic procedures ranges from 0.6% to 2.1%, 
with age, male sex, Parkinson’s disease, and hypertension found to be 
signiﬁ  cant risk factors (Beric et al 2001; Favre et al 2002; Lyons et al 
2004; Binder et al 2005; Gorgulho et al 2005; Sansur et al 2007). It has 
been found that the incidence of intracerebral hemorrhage following either 
thalamic DBS or ablative thalamic lesions for parkinsonian tremor is not 
signiﬁ  cantly different (Blomstedt and Hariz 2006).Neuropsychiatric Disease and Treatment 2008:4(6) 1125
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that an ethics review board oversee DBS clinical trials and 
that a multidisciplinary team provides ongoing input into 
clinical trial design and evaluation (Fins 2003; Nuttin and 
Gybels 2003; Gilbert 2006; Hamani and Moro 2007). Patients 
should be assessed using validated and standardized tests 
(Müller-Vahl 2002), such as the YGTSS (Harcherik et al 
1984), RVBRS, Shapiro TS Severity Scale (Shapiro et al 
1988), and TS Symptom List (Leckman et al 1988), as well 
as a battery of neuropsychological tests (Mink et al 2006; 
Visser-Vandewalle 2007). Preoperatively, MRI should be per-
formed to facilitate stereotactic planning and post-operatively, 
imaging is mandatory to conﬁ  rm electrode placement (Mink 
et al 2006). This would additionally provide visualization of 
the centre of the active contact of stimulation, the positioning 
of which is crucial to avoid DBS failure (Okun et al 2005). 
Since insertion of DBS electrodes can cause a microle-
sion effect (Houeto et al 2005), post-operative assessments 
of DBS efﬁ  cacy should be performed after these possible 
effects have resolved and after stimulation parameters have 
stabilized (Visser-Vandewalle 2007). Assessment of DBS 
effects is recommended to be performed in a double-blind 
fashion. Since DBS for TS remains an experimental therapy, 
its performance should be limited to neurosurgical centres with 
DBS experience in the treatment of movement disorders and 
with collaborations with neurological and psychiatric services 
(Visser-Vandewalle 2007; Visser-Vandewalle et al 2006). 
As is standard with other therapies, patients must be able to 
provide informed consent to participate in clinical trials and 
should be allowed to withdraw from DBS management at any 
time (Mink et al 2006; Nuttin and Gybels 2003). The aim of 
DBS for TS is solely to relieve patients of their symptoms 
and not for political, law enforcement, or social purposes 
(Kopell et al 2004).
Conclusions
In any scientiﬁ  c treatment which is not fully understood there 
is the serious danger of not being able to predict possible 
damage. It should be an inﬂ  exible duty to become thoroughly 
familiar with the drug or procedure to be employed. This 
implies a thorough understanding of the physiological and 
psychobiological functions which may have a bearing on 
the proposed treatment (Diethelm 1939).
Oskar Diethelm’s (1939) advice at that 1938 Annual Meeting 
of the American Psychiatric Association bears relevance even 
seventy years later. Neurosurgical lesion procedures and 
DBS have demonstrated therapeutic promise for a subset of 
patients with TS but have not yet provided sufﬁ  cient evidence 
to justify their use as standard therapies for TS. Lesion studies 
provided the proof-of-principle that TS symptoms could be 
treated using surgery to target speciﬁ  c cerebral structures, but 
are limited by methodologic issues in study design, such as 
their open-label nature (see Table 1), unclear patient inclusion 
and exclusion criteria, and lack of post-operative assessment 
of the size and location of the lesions performed. To date, 
most surgical experiences with DBS also have been described 
in open-label case reports or series with varying degrees of 
success and with inconsistency in the types of post-operative 
assessments performed (Temel and Visser-Vandewalle 2004; 
Neimat et al 2006). Ultimately, improvement of the efﬁ  cacy 
of surgical strategies for TS will require identiﬁ  cation of 
the patients whose tics are most likely to respond to HFS, 
performing comprehensive pre-and post-operative blinded 
and standardized clinical assessments of tic symptoms, and 
determination of the most appropriate surgical target(s) 
for resolution of tic symptomatology. It is anticipated that 
the development of animal models of TS as well as further 
advances in anatomical and functional imaging technologies 
will enhance understanding of TS pathophysiology and so 
lead to the reﬁ  nement of current surgical strategies (Sachdev 
and Sachdev 1997; Sakas et al 2007).
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